Theolytics

Theolytics is focused on developing category changing cancer therapies in the form of oncolytic viruses. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by Oxford Science Innovation (OSI) and international life sciences investors Epidarex Capital, Taiho Ventures, and M Ventures.
For more information, please visit https://www.theolytics.com/

https://www.theolytics.com/

Team Member
more about
Therese Liechtenstein
Latest News Entry
2021/07/08
Theolytics expands Series A financing and welcomes M Ventures as a new investor

Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team.

all portfolio news